Alanine News and Research

RSS

High-dose taurine aggravates alcohol-induced liver injury, study shows

The researchers first tested whether taurine could compensate for reduced intestinal taurine availability and protect against alcohol-induced liver damage.

30 Sep 2026

New study explains how TMEM63B protein regulates cell membranes

An autoinhibitory domain in the C-terminal tail of the TMEM63B, a mechanosensitive lipid scramblase, helps maintain its inactive state under resting conditions, report researchers from Institute of Science Tokyo.

29 Sep 2026

Celastrol reduces cholestatic liver injury by inhibiting specific protein

Cholestasis occurs when bile formation, secretion, or flow is impaired, causing toxic bile acids to accumulate and trigger inflammation and liver-cell damage.

17 Sep 2026

Cannabis-derived nanovesicles showed early antitumor potential in mice

Researchers developed a Cannabis sativa hairy root culture system that produced stable plant-derived nanovesicles capable of promoting dendritic cell maturation and activating T-cell responses through TLR2- and TLR4-associated signaling. Oral administration also restored selected immune responses in immunosuppressed mice and suppressed tumor growth in an E.G7 lymphoma model, providing preliminary evidence for their immunomodulatory and antitumor potential.

15 Sep 2026

What children eat may leave a measurable signature in their blood

Researchers analyzed 236 blood metabolites in 421 children to examine metabolic signatures associated with three dietary patterns characterized by core foods, animal protein sources, or poor-quality fats and sugars. The results identified distinct, biologically plausible metabolite patterns across dietary exposures, although most individual associations did not survive multiple-testing correction and require validation in independent cohorts.

15 Sep 2026

Early studies hint that ketones may affect pathways linked to PTSD

An integrative review found that ketogenic therapy may influence metabolic, inflammatory, oxidative stress, and neurotransmitter pathways implicated in PTSD, with animal studies and small human studies reporting early signs of symptom improvement. Human evidence remains limited to very small cohorts, case reports, and pilot studies, and controlled trials have yet to establish clinical efficacy.

11 Sep 2026

Could scorpion venom inspire new treatments for liver disease?

Scorpion venom peptides show promising anti-inflammatory, antiviral, analgesic, and immunomodulatory effects, with experimental evidence suggesting that some candidates could target pathways involved in chronic liver disease and viral hepatitis. The review highlights Kv1.3-blocking peptides and antiviral compounds as potential therapeutic leads, while emphasizing that limited hepatic efficacy data, poor pharmacokinetics, immunogenicity, and manufacturing challenges must be overcome before clinical translation.

8 Sep 2026

More coffee, higher testosterone? This study found a more complicated picture

Higher habitual coffee intake was associated with a leaner body composition, lower circulating branched-chain amino acids, and distinct cardiometabolic patterns in 2,264 middle-aged Finnish adults. Hormonal associations differed by sex, with broader testosterone- and SHBG-related patterns in men and more limited SHBG-related changes in women.

20 Aug 2026

Genetic analysis of 1 million people points to FNIP1 as a promising metabolic target

Mega-scale exome sequencing of 1,032,116 people identified 59 independent genes linked to the TG:HDL ratio, including 44 rare-coding associations not detected in the previous largest analysis. Ultra-rare FNIP1 loss-of-function variants were associated with favorable fat distribution, lower liver fat and glycemia, and around 60% lower odds of a composite cardiometabolic disease outcome.

7 Aug 2026

Semaglutide and tirzepatide linked to fewer alcohol-related hospital visits

Newer GLP-1 receptor agonists, including semaglutide and tirzepatide, were associated with fewer alcohol-related ED visits or hospitalizations among adults with alcohol use disorder and type 2 diabetes or obesity.

24 Jul 2026

Siemens Healthineers launches an industry-leading menu for core lab capillary testing on Atellica analyzers with claims for 24 assays

Siemens Healthineers announced today that it has launched capillary testing on the Atellica CH, IM, and CI Analyzers after receiving CE-mark for 24 capillary blood testing claims, an advancement for capillary testing that offers clinical labs greater confidence in test results and higher throughput.

From Siemens Healthineers 24 Jul 2026

Deep learning identifies novel compounds against antibiotic-resistant gonorrhea

With tens of millions of annual cases, gonorrhea is the second most frequently reported sexually transmitted infection (STI). Alone in the U.S., over 600,000 cases are reported each year.

17 Jun 2026

Oral semaglutide improves blood sugar, weight, and liver markers in real-world diabetes care

A nationwide Finnish registry study of 7,249 GLP-1RA-naïve adults with type 2 diabetes found that once-daily oral semaglutide was associated with 12-month improvements in HbA1c, body weight, lipid markers, and ALT.

11 Jun 2026

Gut changes linger years after polyp removal and may signal colorectal cancer risk

Researchers found that women who had undergone colorectal adenoma resection still showed gut microbiome and fecal metabolome alterations an average of about 12 years later. These persistent changes partly resembled colorectal cancer-associated patterns, suggesting that the host-microbiome axis may remain altered along the adenoma-cancer continuum.

28 May 2026

One-time gene editing cuts LDL cholesterol in early hypercholesterolemia trial

A phase 1 NEJM interim analysis found that a single infusion of the investigational base-editing therapy VERVE-102 produced dose-dependent reductions in circulating PCSK9 protein and LDL cholesterol in adults with heterozygous familial hypercholesterolemia or premature coronary artery disease.

26 May 2026

Retatrutide reshapes metabolism in obesity and type 2 diabetes, study finds

Retatrutide altered circulating metabolites and lipids linked to fatty acid oxidation and insulin resistance in people with obesity, with or without type 2 diabetes. These biomarker changes suggest improved metabolic health, but the post-hoc analysis remains hypothesis-generating and does not prove direct clinical benefit.

26 May 2026

How Andes virus super-spreaders reveal the risk behind the MV Hondius hantavirus cluster

A 2020 NEJM study of the 2018 to 2019 Epuyén outbreak showed that Andes virus spread from one zoonotic introduction into four generations of human infection, causing 34 cases and 11 deaths. The findings are newly relevant after WHO reported an ANDV cluster linked to the MV Hondius cruise ship, where close indoor exposure may have enabled onboard human-to-human transmission.

14 May 2026

Liver fat may disrupt post-meal glucagon control in early type 2 diabetes

Researchers found that MASLD, rather than type 2 diabetes alone, was linked to higher fasting glucagon levels in adults with newly diagnosed diabetes and matched controls. In people with early type 2 diabetes, higher liver fat was specifically associated with exaggerated early post-meal glucagon responses, independent of insulin sensitivity, visceral fat, amino acids, or NEFAs.

10 May 2026

Study debunks steroid myths, framing creatine as an essential energy-providing molecule

Creatine, a compound often associated with gym-goers and athletes, has long been touted as a performance-enhancing supplement. But beyond the hype, what does science actually reveal about its effects on the body and mind?

4 May 2026

Long-term study supports tenofovir alafenamide for chronic hepatitis B

Tenofovir alafenamide (TAF) has demonstrated comparable efficacy to tenofovir disoproxil fumarate (TDF), with improved renal and bone safety, in Chinese participants with chronic hepatitis B enrolled in two Phase 3 trials.

24 Apr 2026